CA2690913C - Ire-1.alpha. inhibitors - Google Patents

Ire-1.alpha. inhibitors Download PDF

Info

Publication number
CA2690913C
CA2690913C CA2690913A CA2690913A CA2690913C CA 2690913 C CA2690913 C CA 2690913C CA 2690913 A CA2690913 A CA 2690913A CA 2690913 A CA2690913 A CA 2690913A CA 2690913 C CA2690913 C CA 2690913C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
ire
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2690913A
Other languages
English (en)
French (fr)
Other versions
CA2690913A1 (en
Inventor
John Bruce Patterson
David Gregory Lonergan
Gary A. Flynn
Qingping Zeng
Peter V. Pallai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fosun Orinove Pharmatech Inc
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Priority to CA2963784A priority Critical patent/CA2963784A1/en
Publication of CA2690913A1 publication Critical patent/CA2690913A1/en
Application granted granted Critical
Publication of CA2690913C publication Critical patent/CA2690913C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/44—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/61—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
    • C07C223/02—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/02—Thiols having mercapto groups bound to acyclic carbon atoms
    • C07C321/04—Thiols having mercapto groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/55—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C07C65/26—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/30—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/48—Aldehydo radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA2690913A 2007-06-08 2008-06-09 Ire-1.alpha. inhibitors Expired - Fee Related CA2690913C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2963784A CA2963784A1 (en) 2007-06-08 2008-06-09 Ire-1.alpha. inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94274307P 2007-06-08 2007-06-08
US60/942,743 2007-06-08
PCT/US2008/066310 WO2008154484A1 (en) 2007-06-08 2008-06-09 Ire-1a inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2963784A Division CA2963784A1 (en) 2007-06-08 2008-06-09 Ire-1.alpha. inhibitors

Publications (2)

Publication Number Publication Date
CA2690913A1 CA2690913A1 (en) 2008-12-18
CA2690913C true CA2690913C (en) 2017-05-23

Family

ID=39730581

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2690913A Expired - Fee Related CA2690913C (en) 2007-06-08 2008-06-09 Ire-1.alpha. inhibitors
CA2963784A Abandoned CA2963784A1 (en) 2007-06-08 2008-06-09 Ire-1.alpha. inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2963784A Abandoned CA2963784A1 (en) 2007-06-08 2008-06-09 Ire-1.alpha. inhibitors

Country Status (8)

Country Link
US (5) US7858666B2 (enExample)
EP (4) EP2520561B1 (enExample)
JP (4) JP4827986B2 (enExample)
CN (2) CN102015606B (enExample)
CA (2) CA2690913C (enExample)
ES (2) ES2569660T3 (enExample)
MX (1) MX2009013332A (enExample)
WO (1) WO2008154484A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015606B (zh) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1α抑制剂
WO2011011716A1 (en) * 2009-07-23 2011-01-27 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
EP2496230B1 (en) * 2009-11-03 2020-02-26 Fosun Orinove Pharmatech, Inc. Ire-1 alpha inhibitors
EP3409276B1 (en) * 2010-04-05 2020-12-30 Fosun Orinove Pharmatech, Inc. Ire-1a inhibitors
TWI562977B (en) * 2010-11-05 2016-12-21 Bayer Ip Gmbh Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation
WO2012109238A2 (en) * 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
EP2694059A4 (en) 2011-04-04 2014-10-15 Univ Georgetown SMALL MOLECULAR INHIBITORS OF XBP1 SPLICE
US8927593B2 (en) * 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections
WO2013134774A1 (en) 2012-03-09 2013-09-12 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
CA2867085A1 (en) 2012-04-23 2013-10-31 Imba - Institut Fur Molekulare Biotechnologie Gmbh Archease as rna ligase complex member
BR112015006828A8 (pt) 2012-09-26 2019-09-17 Univ California composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
EP3055287B1 (en) * 2013-10-08 2019-11-06 Lu, Qing-Bin Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
JPWO2015136887A1 (ja) * 2014-03-10 2017-04-06 国立大学法人広島大学 滑膜細胞増殖抑制剤及び滑膜細胞の増殖抑制方法
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US20160106721A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
EP3656382A1 (en) 2017-01-30 2020-05-27 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
CN106974908B (zh) * 2017-03-02 2019-11-12 深圳大学 含有hdac抑制剂和ire1抑制剂的药物组合物及用途
CN106822904B (zh) * 2017-03-08 2019-10-25 暨南大学 含akt抑制剂和ire1抑制剂的药物组合物及其应用
CN107308178B (zh) * 2017-07-31 2020-11-10 苏州大学附属儿童医院 一种用于肠外营养相关性肝病药物
ES2938278T3 (es) * 2018-03-27 2023-04-05 Neuropore Therapies Inc Compuestos como moduladores de la señalización de TLR2
MA53105A (fr) 2018-07-03 2021-05-12 Univ Illinois Activateurs de la réponse à une protéine non dépliée
WO2020019107A1 (en) * 2018-07-23 2020-01-30 Fosun Orinove Pharmatech, Inc. IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT
EP3826634A4 (en) * 2018-07-23 2022-05-04 Fosun Orinove Pharmatech, Inc. Ire1 alpha inhibitor in combination with cancer therapeutic agent for cancer treatment
AU2018447495A1 (en) * 2018-11-02 2021-06-17 Fosun Orinove Pharmatech, Inc. IRE1α inhibitor in combination with cancer therapeutic agent for cancer treatment
SG11202109936YA (en) 2019-03-26 2021-10-28 Neuropore Therapies Inc Compounds and compositions as modulators of tlr signaling
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
CN118576600A (zh) * 2024-05-31 2024-09-03 中山大学附属第三医院 IRE1α抑制剂KIRA8在制备治疗复发难治多发性骨髓瘤的药物中的应用

Family Cites Families (404)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE209910C (enExample)
US675543A (en) 1899-08-05 1901-06-04 Farbenfabriken Elberfeld Co Derivatives of aromatic oxy-aldehydes and process of making same.
US2346662A (en) * 1940-04-08 1944-04-18 Universal Oil Prod Co Suppression of metal catalysis
US2282907A (en) 1941-05-01 1942-05-12 Us Rubber Co Parasiticide
US2649444A (en) 1948-10-19 1953-08-18 Burroughs Wellcome Co Process for the preparation of amino ketones
US2778853A (en) 1952-09-10 1957-01-22 Merck & Co Inc Deamination process
US2771391A (en) 1953-08-20 1956-11-20 Allied Lab Inc Physiologically active p-alkoxy-beta-piperidinopropiophenones causing cns depressantand anesthetic effects in animals
US2712031A (en) * 1953-10-27 1955-06-28 Lasdon Foundation Inc Monosubstituted salicylaldehyde alkoximes
US3080372A (en) 1960-03-25 1963-03-05 Res Lab Dr C Janssen 1-aroylalkyl-4-arylpiperidine derivatives
CH402859A (de) 1960-05-24 1965-11-30 Wander Ag Dr A Verfahren zur Herstellung von a-Pyrrolidino-valerophenonen
US3151124A (en) 1961-11-20 1964-09-29 Ciba Geigy Corp Alpha oxy-beta alkyl-gamma tertiary amino-alpha phenyl propanes
US3252996A (en) 1962-10-02 1966-05-24 Ciba Geigy Corp Alpha-pyrrolidinomethyl valero and caprophenones
BE633437A (enExample) 1962-06-11
US3203962A (en) 1962-10-11 1965-08-31 Ciba Geigy Corp Alpha-phenyl-beta pyrrolidino-propiophenones
US3148997A (en) 1963-01-04 1964-09-15 Dow Chemical Co Catechol compounds in improving clays and clay-containing materials
US3211613A (en) 1963-01-14 1965-10-12 Merck & Co Inc Anticoccidial compositions and method of using same
FR1453234A (fr) 1964-02-18 1966-06-03 Pechiney Progil Sa Nouveaux composés fongicides à usage agricole
US3340300A (en) 1964-10-05 1967-09-05 American Cyanamid Co Trimethoxy benzoylacetaldehyde oximes
CH445193A (de) 1964-12-14 1967-10-15 Agripat Sa Fungizides Mittel und seine Verwendung
FR1437423A (fr) * 1964-12-29 1966-05-06 Pechiney Progil Sa Composés fongicides nouveaux à usage agricole dérivés de l'aldéhyde salicylique
US3816433A (en) 1965-03-24 1974-06-11 Ferrosan Ab 4-fluoro-ypsilon-(4-methylpiperidino)-butyrophenone and its pharmaceutically acceptable salts
US3325521A (en) 1965-07-19 1967-06-13 Parke Davis & Co Halogenated cresol compounds and methods for their production
US3417087A (en) 1965-12-27 1968-12-17 Research Corp 3(aminopropionyl)benzothiophenes
CH479246A (de) 1966-10-28 1969-10-15 Ciba Geigy Mittel zur Bekämpfung von phytopathogenen Pilzen und Bakterien
FR1588756A (enExample) 1967-05-26 1970-03-16 Pepro
DE1679900A1 (de) * 1967-09-07 1971-04-08 Agfa Gevaert Ag Verfahren zum Verkleben von Polyesterfilmen
US3681445A (en) 1968-01-19 1972-08-01 Merck & Co Inc Substituted phenyl benzoic acid compounds
DE1989548U (de) 1968-03-29 1968-07-18 Karl Muenkel K G Zwei- oder mehrteiliger badezimmerschrank aus kunststoff.
US3721741A (en) 1968-10-28 1973-03-20 Ciba Geigy Ag Combatting phytopathogenic fungi on plants with sub-phytoloxic fungicidally effective amounts of herbicidal n-phenyl derivatives of 3,5-dihalo-salicylaldehyde
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3651085A (en) 1969-04-14 1972-03-21 Robins Co Inc A H 1-(omega-benzoylalkyl)-3-substituted pyrrolidines
US3703527A (en) 1969-06-04 1972-11-21 Hoffmann La Roche Preparation of mannich-bases
DE2021470A1 (de) 1970-05-02 1971-11-25 Cassella Farbwerke Mainkur Ag Piperazinderivate
FR2092133B1 (enExample) 1970-05-06 1974-03-22 Orsymonde
US3714226A (en) 1970-06-09 1973-01-30 Merck & Co Inc Phenyl benzoic acid compounds
DE2142245C3 (de) * 1971-08-24 1980-09-04 Basf Ag, 6700 Ludwigshafen Farbstoffe auf der Basis von Imino-isoindolin, deren Herstellung und Verwendung als Pigmente für Lacke und zum Anfärben von Polyestermaterialien
US3969356A (en) 1971-09-13 1976-07-13 Kali-Chemie Aktiengesellschaft N-[3-(p-f-benzoyl)-propyl]-N'-[2.(nitro,nitro-el, or methoxyphenyl)-ethyl]-p
US3806526A (en) 1972-01-28 1974-04-23 Richardson Merrell Inc 1-aroylalkyl-4-diphenylmethyl piperidines
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3962459A (en) 1973-09-04 1976-06-08 Sandoz, Inc. Lipidemia treatment with p-phenoxy-alkylphenone compositions
US3873539A (en) 1973-10-03 1975-03-25 Sandoz Ag Substituted-4-aminoacetyl alkanoylphenones
US3992546A (en) 1973-10-18 1976-11-16 Ciba-Geigy Corporation 4-Piperidinobutyrophenones as neuroleptics
US4054570A (en) 1973-10-18 1977-10-18 Ciba-Geigy Corporation 4-Piperidinobutyrophenones
US3944064A (en) 1973-10-26 1976-03-16 Alza Corporation Self-monitored device for releasing agent at functional rate
US3995047A (en) 1973-12-14 1976-11-30 Eisai Co., Ltd. Propiophenone derivatives in the treatment of pathological muscular conditions
US3912755A (en) 1974-01-30 1975-10-14 Lilly Co Eli Preparation of pharmaceutical intermediates
US3931197A (en) 1974-02-08 1976-01-06 Richardson-Merrell Inc. Substituted piperidine derivatives
IL48319A0 (en) 1974-10-26 1975-12-31 Merck Patent Gmbh Araliphatic nitrogen compounds and a process for their preparation
US4028366A (en) 1975-01-20 1977-06-07 Sterling Drug Inc. 2-Naphthyl-lower-alkanoylamines
US4169892A (en) 1975-04-03 1979-10-02 Innothera 1-(benzothien-2'-yl)-3-morpholino propanones and therapeutic compositions containing same
US4066788A (en) 1975-10-03 1978-01-03 Richardson-Merrell Inc. Substituted benzaldehyde hypolipidemic agents
DE2557341A1 (de) 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4333941A (en) 1975-12-22 1982-06-08 The Dow Chemical Company Inhibition of enveloped viruses with phenyl ketones
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4015014A (en) 1976-03-17 1977-03-29 The Dow Chemical Company Method for the use of aryl azines as anthelmintics
DE2620254C2 (de) 1976-05-07 1984-03-15 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Hydroxybenzaldehyden
IT1068110B (it) 1976-08-13 1985-03-21 Montedison Spa Processo per la preparazione di aldeidi 2 idrossibenzoiche
US4072852A (en) * 1976-08-23 1978-02-07 Honeywell Inc. Digital computer monitoring and restart circuit
US4072582A (en) 1976-12-27 1978-02-07 Columbia Chemical Corporation Aqueous acid plating bath and additives for producing bright electrodeposits of tin
US4183553A (en) * 1977-02-04 1980-01-15 Ciba-Geigy Corporation Pressure- or heat-sensitive recording material and novel chromano compounds used therein
DE2718405A1 (de) 1977-04-26 1978-11-02 Boehringer Sohn Ingelheim Neue n- eckige klammer auf 1-(3-benzoylpropyl)-4-piperidyl eckige klammer zu -sulfonsaeureamide und verfahren zu deren herstellung
US4176198A (en) 1977-10-06 1979-11-27 William H. Rorer, Inc. Method of treatment
US4311841A (en) * 1977-11-21 1982-01-19 Petrolite Corporation Process of preparing hexahydropyrimidines
JPS54110321A (en) 1978-02-20 1979-08-29 Ajinomoto Co Inc Insecticide
JPS54125630A (en) 1978-02-22 1979-09-29 Nippon Zoki Pharmaceutical Co Novel propanone derivative*its manufacture and medical composition containing it as active component
JPS54163538A (en) 1978-06-13 1979-12-26 Sumitomo Chemical Co Production of salycilaldehydes
US4230727A (en) 1979-04-02 1980-10-28 William H. Rorer, Inc. Compositions and method of treatment
JPS606339B2 (ja) 1979-04-28 1985-02-18 ダイキン工業株式会社 フツ素化方法
FR2475044A1 (fr) * 1980-02-04 1981-08-07 Anvar Derives de nitro-2 naphtofurannes, leur preparation et leur application notamment comme regulateurs de la croissance cellulaire
DE3019496A1 (de) 1980-05-22 1981-11-26 Bayer Ag, 5090 Leverkusen Aminopropanol-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
DE3019497A1 (de) 1980-05-22 1981-11-26 Bayer Ag, 5090 Leverkusen Aminopropiophenon-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
FR2486523A1 (fr) 1980-07-11 1982-01-15 Rhone Poulenc Ind Procede de preparation de polyphenols comportant eventuellement un groupement aldehyde
GB2080803B (en) * 1980-07-28 1984-01-18 Pfizer Hypoglycemic 5-substituted oxazolidine-2,4-diones
DE3101750A1 (de) 1981-01-21 1982-08-26 Basf Ag, 6700 Ludwigshafen Verfahren zur kontinuierlichen herstellung von ethanol
US4381308A (en) 1981-04-23 1983-04-26 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4507268A (en) * 1982-01-25 1985-03-26 Henkel Corporation Solvent extraction
JPS58181971A (ja) 1982-04-15 1983-10-24 松下電器産業株式会社 自動車用キ−レスエントリ装置
JPS5944371A (ja) 1982-09-07 1984-03-12 Dainippon Pharmaceut Co Ltd １―フエニル―２―メチル―３―（１―ピロリジニル）―１―プロパノン誘導体
FR2534912B1 (fr) 1982-10-26 1985-06-28 Lafon Labor Nouveaux derives de (2,4,6-trimethoxyphenyl) - (3-piperidinopropyl) -cetone, utilisation en therapeutique et procede de preparation
DE3332780A1 (de) 1983-09-10 1985-03-28 Hoechst Ag, 6230 Frankfurt 6-sulfoxyphenolderivate, ihre herstellung und ihre verwendung als cytoprotekiva
US4686235A (en) 1983-10-12 1987-08-11 Merck & Co., Inc. Substituted cinnamyl-2,3-dihydrobenzofuran and analogs useful as anti-inflammatory agents
HU33131A (enExample) 1984-01-26 1984-10-29
US4544663A (en) 1984-05-07 1985-10-01 Sandoz, Inc. Indolamine derivatives as anti-fertility agents
DE3436450A1 (de) 1984-10-05 1986-04-10 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von p-aminoethylketonen
US5057535A (en) 1985-04-11 1991-10-15 Nippon Kayaku Kabushiki Kaisha Derivatives of an aminoketone
FR2584715B1 (fr) 1985-07-10 1987-10-09 Lafon Labor Phenyl-(3-hexamethyleneiminopropyl)-cetone, procede de preparation et utilisation en therapeutique
FR2597864B1 (fr) 1986-04-28 1990-11-16 Lafon Labor Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique
US5571886A (en) 1986-12-23 1996-11-05 Shipley Company, Inc. Aromatic novolak resins
JPH0637389B2 (ja) 1986-12-26 1994-05-18 北陸製薬株式会社 頻尿治療剤
JPS63243085A (ja) * 1987-03-30 1988-10-07 Toray Ind Inc 新規スピロナフトピラン化合物
FR2618145B1 (fr) 1987-07-17 1989-11-24 Rhone Poulenc Chimie Procede de chloration selective de composes phenoliques
US4847429A (en) 1987-08-03 1989-07-11 Eastman Kodak Company Synthesis of phenylhydroquinones
US4927956A (en) 1987-09-16 1990-05-22 Hoechst Celanese Corporation 3,5-disubstituted-4-acetoxystyrene and process for its production
US5025036A (en) 1987-10-01 1991-06-18 Hoffmann-La Roche Inc. Catechol carboxylic acids
JPH0256469A (ja) * 1987-12-08 1990-02-26 Kumiai Chem Ind Co Ltd ピリミジン誘導体及び除草剤
JPH02264946A (ja) 1989-04-05 1990-10-29 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH085780B2 (ja) 1989-04-28 1996-01-24 呉羽化学工業株式会社 変形性関節症治療剤
EP0435827A3 (en) 1989-12-28 1991-11-13 Ciba-Geigy Ag Diaza compounds
DE4012008A1 (de) 1990-04-13 1991-10-17 Bayer Ag Verfahren zur herstellung von o-hydroxy-benzaldehyden
US5025006A (en) 1990-06-26 1991-06-18 Merck & Co., Inc. 2-biphenyl-carbapenem antibacterial agents
EP0467434A1 (en) 1990-06-26 1992-01-22 Merck & Co. Inc. 2-Biphenyl-carbapenem antibacterial agents
EP0464900A3 (en) 1990-06-26 1992-07-22 Merck & Co. Inc. 2-biphenyl-carbapenems
US5202355A (en) 1991-06-12 1993-04-13 Takasago Institute For Interdisciplinary Science Inc. Method of inhibiting aldose reductase in diabetic hosts using phenol derivatives
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
JPH05127335A (ja) 1991-10-14 1993-05-25 Fuji Photo Film Co Ltd 熱現像拡散転写型カラー感光材料
JPH05127330A (ja) 1991-11-06 1993-05-25 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の処理方法
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
GB9127279D0 (en) 1991-12-23 1992-02-19 Ici Plc Heterocyclic derivatives
FR2689505B1 (fr) 1992-04-03 1995-06-09 Rhone Poulenc Chimie Procede d'hydroxylation de composes phenoliques.
WO1993021184A1 (en) 1992-04-10 1993-10-28 Zeneca Limited Biphenylylquinuclidine derivatives as squalene synthase inhibitors
US5198422A (en) 1992-06-11 1993-03-30 Smithkline Beecham Corporation Stabilized somatotropin for parenteral administration
GB9217723D0 (en) 1992-08-20 1992-09-30 Ici Plc Chemical process
JPH06135153A (ja) 1992-10-29 1994-05-17 Fuji Photo Film Co Ltd 感熱記録材料
FR2698353B1 (fr) 1992-11-25 1995-02-17 Rhone Poulenc Chimie Procédé de O-alkylation des composés phénoliques.
AU6219994A (en) 1993-03-11 1994-09-26 Yamanouchi Pharmaceutical Co., Ltd. Compound with vasopressin antagonism
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
WO1994022826A1 (en) 1993-04-07 1994-10-13 Otsuka Pharmaceutical Co., Ltd. Peripheral vasodilating agent containing n-acylated 4-amino piperidine derivatives as active ingredients
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
GB9308652D0 (en) 1993-04-27 1993-06-09 Wellcome Found Anti-inflammatory compounds
JPH06332264A (ja) 1993-05-24 1994-12-02 Hodogaya Chem Co Ltd 静電荷像現像用トナー
JPH0784415A (ja) 1993-06-25 1995-03-31 Hodogaya Chem Co Ltd 正帯電性トナー用摩擦帯電付与部材
DK77393D0 (da) 1993-06-29 1993-06-29 Novo Nordisk As Aktivering af enzymer
WO1995001326A1 (en) 1993-06-30 1995-01-12 The Wellcome Foundation Limited Anti-atherosclerotic diaryl compounds
IT1266582B1 (it) 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
US5905080A (en) 1993-08-20 1999-05-18 Smithkline Beecham, P.L.C. Amide and urea derivatives as 5HT1D receptor antagonists
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US5420362A (en) 1993-10-08 1995-05-30 Clairol, Inc. Synthesis of 2-methyl-1-naphthol
WO1995015954A1 (en) 1993-12-07 1995-06-15 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
DE69423858T2 (de) 1993-12-17 2000-07-27 Fuji Photo Film Co., Ltd. Positiv-arbeitende Fotolackzusammensetzung
JPH09506885A (ja) 1993-12-21 1997-07-08 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ▲下１ｄ▼（抗うつ作用）活性を有するインドール、インドリンおよびキノリン誘導体
GB9326008D0 (en) 1993-12-21 1994-02-23 Smithkline Beecham Plc Novel compounds
US5565416A (en) 1994-01-10 1996-10-15 Phillips Petroleum Company Corrosion inhibitor for wellbore applications
US5654260A (en) 1994-01-10 1997-08-05 Phillips Petroleum Company Corrosion inhibitor for wellbore applications
CA2184002A1 (en) 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
WO1995026328A1 (en) 1994-03-26 1995-10-05 Smithkline Beecham Plc Biphenyl derivatives as 5ht1d antagonists
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
JPH09512804A (ja) 1994-05-06 1997-12-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ１ｄアンタゴニストとして有用なビフェニルカルボキシアミド類
US5756496A (en) 1994-05-28 1998-05-26 Smithkline Beecham P.L.C. Amide derivatives having 5HT1D-antagonist activity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
DE4423061C1 (de) 1994-07-01 1996-01-18 Hoechst Ag Verfahren zur Herstellung von Biphenylen mit Palladacyclen als Katalysatoren
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5579110A (en) 1994-08-31 1996-11-26 Honeywell Inc. In-line multiple rotation sensor assembly
CA2158191A1 (en) 1994-09-16 1996-03-17 Junji Yokoi Method for preventing settlement of aquatic fouling organisms
US5599974A (en) 1994-09-19 1997-02-04 Center For Innovative Technology Aldehydic agents for allosteric modification of hemoglobin
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
GB9421003D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
US6214994B1 (en) 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
US5705501A (en) 1994-11-17 1998-01-06 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-morpholinopropanones to treat Alzheimer's Disease
DE4444244A1 (de) * 1994-12-13 1996-06-20 Basf Ag Photochrome Spiroindoline
JPH10510821A (ja) 1994-12-22 1998-10-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 四環式スピロ化合物、その製法およびその５ｈｔ１ｄレセプターアンタゴニストとしての使用
WO1996021661A1 (en) 1995-01-12 1996-07-18 Glaxo Group Limited Piperidine derivatives having tachykinin antagonist activity
ES2151652T3 (es) 1995-02-02 2001-01-01 Smithkline Beecham Plc Derivados de indol como antagonistas del receptor 5ht.
AU5147196A (en) 1995-03-27 1996-10-16 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic a gents
AU711968B2 (en) 1995-04-04 1999-10-28 Encysive Pharmaceuticals Inc. Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
GB9508637D0 (en) 1995-04-28 1995-06-14 Fujisawa Pharmaceutical Co New use
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
EP0783502A1 (en) 1995-08-02 1997-07-16 J. URIACH & CIA. S.A. New carboxamides with antifungal activity
GB9519033D0 (en) 1995-09-18 1995-11-15 Smithkline Beecham Plc Treatment
FR2739098B1 (fr) 1995-09-25 1997-11-28 Rhone Poulenc Chimie Procede d'acylation d'un compose aromatique
GB9522845D0 (en) 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
EP0862565A1 (en) 1995-11-22 1998-09-09 Smithkline Beecham Plc Tricyclic spiro compounds as 5ht 1d? receptor antagonists
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
JPH09149797A (ja) 1995-11-30 1997-06-10 Internatl Reagents Corp 酵素、抗原又は抗体の定量方法及び酵素活性測定用の基質
HUP9900143A3 (en) 1995-12-06 2000-04-28 Astra Pharmaceuticals Ltd King Pharmaceutically useful 3-pyridil-compounds
FR2744720B1 (fr) 1996-02-09 1998-04-10 Rhone Poulenc Chimie Procede d'hydroxylation de composes phenoliques
FR2745287B1 (fr) 1996-02-28 1998-04-10 Rhone Poulenc Chimie Nouvelle composition catalytique et sa mise en oeuvre dans un procede d'acylation d'un compose aromatique
FR2745285B1 (fr) 1996-02-28 1998-04-10 Rhone Poulenc Chimie Nouveau catalyseur de c-alkylation d'un compose aromatique et son utilisation
GB9605945D0 (en) 1996-03-21 1996-05-22 Smithkline Beecham Plc Novel compounds
GB9606370D0 (en) 1996-03-26 1996-06-05 Dormer Tools Sheffield Ltd Improvements in or relating to twist drills
GB9606396D0 (en) 1996-03-27 1996-06-05 Smithkline Beecham Plc Novel compounds
JP2000507253A (ja) 1996-03-27 2000-06-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アザスピロ誘導体
GB9607219D0 (en) 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
WO1997048786A1 (de) 1996-06-19 1997-12-24 Call Hans Peter Mehrkomponentensystem zur verwendung mit waschaktiven substanzen
PT920312E (pt) 1996-07-08 2005-04-29 Galderma Res & Dev Derivados de adamantilo indutores de apoptose e sua utilizacao como agentes anticancerigenos
US6462064B1 (en) 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
WO1998004508A1 (fr) 1996-07-31 1998-02-05 Shionogi & Co., Ltd. NOUVEAUX COMPOSES DE p-TERPHENYL
JP3202607B2 (ja) * 1996-08-01 2001-08-27 帝人株式会社 ２−（４−アルコキシ−３−シアノフェニル）チアゾール誘導体の製造法
DE19631131A1 (de) 1996-08-01 1998-02-05 Consortium Elektrochem Ind Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
FR2752165B1 (fr) * 1996-08-12 1998-10-09 Intertechnique Sa Equipement de protection respiratoire a mise en place rapide
US5668182A (en) 1996-08-19 1997-09-16 Virginia Commonwealth University Method of calming or sedating an animal with a hydroxy benzaldehyde compound
ATE317381T1 (de) 1996-10-11 2006-02-15 Warner Lambert Co Sulfonamid-substituierte asparaginsäuren als inhibitoren von interleukin-1beta-konvertierenden enzymen
FR2754533B1 (fr) 1996-10-14 1998-11-27 Rhodia Chimie Sa Procede de preparation selective d'un acide 2-hydroxybenzoique et d'un 4-hydroxybenzaldehyde et derives
FR2756278B1 (fr) 1996-11-22 1998-12-31 Rhodia Chimie Sa Procede de preparation d'un 4-hydroxybenzaldehyde et derives
FR2756279B1 (fr) 1996-11-27 1999-01-22 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
US6005009A (en) 1997-03-19 1999-12-21 Duke University Method of inhibiting fibrosis with pyridoxal benzoyl hydrazone and analogs thereof
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
IL132522A0 (en) 1997-04-22 2001-03-19 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and pharmaceutical compositions containing the same
US6288276B1 (en) 1997-05-21 2001-09-11 Henkel Kommanditgeselschaft Auf Aktien Salicylaldoximes and method of preparation
US6013841A (en) 1997-07-17 2000-01-11 Dakota Gasification Company Method for the conversion of 3- and 4-methylcatechol to benzaldehyde
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
US6174656B1 (en) 1997-09-30 2001-01-16 Fuji Photo Film Co., Ltd. Silver halide photographic light-sensitive material, aromatic aldehyde derivative compound, and image-forming method
US6124507A (en) 1997-12-10 2000-09-26 Union Carbide Chemicals & Plastics Technology Corporation Electron donors
PL340958A1 (en) 1997-12-19 2001-03-12 Merck & Co Inc Derivatives of aryl thiazolydinone
US6265142B1 (en) 1998-02-20 2001-07-24 Fuji Photo Film Co., Ltd. Heat developable color photographic light-sensitive material
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6340685B1 (en) 1998-05-22 2002-01-22 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6265395B1 (en) 1998-06-25 2001-07-24 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
YU78600A (sh) 1998-06-26 2002-11-15 Pfizer Products Inc. Poboljšani postupak dobijanja adukta schiff-ove baze amina sa 0-hidroksi aldehidima i na njima baziranih formulacija materijala
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
ES2257864T3 (es) 1998-07-10 2006-08-01 Massachusetts Institute Of Technology Ligandos para metales y procesos mejorados catalizados por metales basados en los mismos.
JP2000026438A (ja) 1998-07-14 2000-01-25 Fujimoto Brothers:Kk 新規な２−（ｎ−シアノイミノ）チアゾリジン−４− オン誘導体
CA2343101A1 (en) 1998-09-11 2000-03-23 Ajinomoto Co., Inc. Benzene derivatives and medicinal use thereof
ATE289507T1 (de) 1998-10-08 2005-03-15 Allergan Inc Rar-antagonisten zur verhütung für männer
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
EP1053989B1 (en) 1999-05-20 2007-07-25 Ciba SC Holding AG Hydroxydiphenyl ether compounds
KR20020012310A (ko) 1999-07-15 2002-02-15 다께우찌 마사야쓰 복소 방향환 화합물
AU6315300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
WO2001014314A1 (en) 1999-08-20 2001-03-01 Nippon Kayaku Kabushiki Kaisha Benzene derivatives having aromatic substituents and processes for the preparation thereof
JP2003529543A (ja) 1999-08-24 2003-10-07 ヴァージニア コモンウェルス ユニバーシティ 置換キラル・アロステリック・ヘモグロビン調節剤
US6515003B1 (en) 1999-08-31 2003-02-04 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of diabetes and other diseases
DE19942700C1 (de) 1999-09-07 2001-04-05 Consortium Elektrochem Ind Verfahren zur Herstellung cyclischer N-Hydroxydicarboximide
HRP20020324A2 (en) 1999-10-13 2003-08-31 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors
US6380229B1 (en) 1999-11-12 2002-04-30 Fujimoto Co., Ltd. 2-(N-cyanoimino)thiazolidin-4-one derivatives
JP2001215669A (ja) 1999-11-25 2001-08-10 Fuji Photo Film Co Ltd 熱現像カラー感光材料
US6329129B1 (en) 1999-11-25 2001-12-11 Fuji Photo Film Co., Ltd. Heat-developable color light-sensitive material
KR20010074549A (ko) 2000-01-25 2001-08-04 고사이 아끼오 키랄 구리 착물, 이의 제조 방법 및 이를 이용한 비대칭합성
US20030187233A1 (en) 2000-02-04 2003-10-02 Masanobu Onishi Perfluoroisopropybenzene derivative
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
EP1136080A3 (en) 2000-03-14 2002-06-05 Pfizer Products Inc. Use of o-vanillin and o-vanillin/trolox combinations
WO2001074762A2 (en) * 2000-04-03 2001-10-11 Phycogen, Inc. Arylsulfates and their use as enhancers or inhibitors of bioadhesion to surfaces
US6861444B2 (en) 2000-04-28 2005-03-01 Asahi Kasei Pharma Corporation Bicyclic compounds
JP2001335476A (ja) 2000-05-29 2001-12-04 Shionogi & Co Ltd 三環化合物の新規用途
AR029686A1 (es) 2000-06-22 2003-07-10 Dow Agrosciences Llc Compuestos de 2-(3,5-disustituido-4-piridil)-4-(tienilo, tiazolilo o arilfenil)-1,3-oxazolina, composiciones y metodos para el control de insectos o acaros y/o plantas utilizando dichos compuestos
MXPA03000174A (es) 2000-07-06 2003-09-22 Neurogen Corp Ligandos de receptor de hormona concentradora de melanina.
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
EP1178036A1 (en) 2000-08-04 2002-02-06 Aventis Cropscience S.A. Fungicidal phenylimidate derivatives
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
DE10040051A1 (de) 2000-08-11 2002-02-21 Basf Ag Derivate des 4-(Trifluormethyl)-phenols sowie Derivate des 4-(Trifluormethylphenyl)-2-(tetrahydropyranyl)ethers und Verfahren zu ihre Herstellung
DE10046272A1 (de) 2000-09-19 2002-03-28 Merck Patent Gmbh Aminoheterocyclen (Faktor Xa Inhibitoren 14)
DE10047109A1 (de) 2000-09-22 2002-04-11 Bayer Ag Verfahren zur Herstellung von DELTA·1·-Pyrrolinen
DE10047111A1 (de) 2000-09-22 2002-04-11 Bayer Ag Verfahren zur Herstellung von DELTA·1·-Pyrrolinen
IL145684A (en) 2000-10-04 2007-06-17 Warner Lambert Co Medications for the treatment of pulmonary hypertension
CA2427184A1 (en) 2000-11-22 2002-05-30 Novartis Ag Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
AU2002223966A1 (en) 2000-12-20 2002-07-01 Warner Lambert Company Non-halogenated naphthol compounds and antimicrobial compositions containing the same
JP2002275165A (ja) 2001-01-12 2002-09-25 Sumitomo Pharmaceut Co Ltd トリアゾール誘導体
JP2004520348A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジン誘導体
DE10102341A1 (de) 2001-01-19 2002-08-08 Ralf Steffens Profilkontur einer Schraubenspindelpumpe
JP2004525118A (ja) * 2001-01-22 2004-08-19 アルパイダ　アーゲー 新規ヒドラゾン類
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
US20030022923A1 (en) 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
CA2473156A1 (en) 2001-03-08 2002-09-19 Incyte San Diego, Inc. Rxr activating molecules
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2002081442A2 (de) 2001-04-09 2002-10-17 Bayer Cropscience Ag Verfahren zum herstellen von δ1-pyrrolinen
ATE460163T1 (de) 2001-04-12 2010-03-15 Pharmacopeia Llc Arly und diaryl piperidinderivate verwendbar als mch-hemmer
US7109193B2 (en) 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
US7326700B2 (en) 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
AU2002310187A1 (en) * 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
KR100575944B1 (ko) 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
US6605620B1 (en) 2001-08-30 2003-08-12 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
US6867221B2 (en) 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
US20030134853A1 (en) 2001-09-26 2003-07-17 Priestley Eldon Scott Compounds useful for treating hepatitis C virus
CN1561337A (zh) 2001-10-05 2005-01-05 惠氏公司 2－基苯并二氢吡喃衍生物的立体有择合成方法
DE10150335A1 (de) 2001-10-15 2003-04-24 Degussa Neue chirale Liganden und deren Übergangsmetallkomplexe sowie deren katalytische Anwendung
JP4581321B2 (ja) 2001-10-23 2010-11-17 住友化学株式会社 不飽和有機化合物誘導体の製造方法
US20060287337A1 (en) 2001-11-09 2006-12-21 Proteologics, Inc. Trans-golgi network-associated processes, methods and compositions related thereto
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
JP2003229174A (ja) * 2002-01-31 2003-08-15 Sanyo Electric Co Ltd フィルム状外装体を用いた非水電解質二次電池
WO2003065789A2 (en) 2002-02-08 2003-08-14 Merck & Co., Inc. N-biphenylmethyl aminocycloalkanecarboxamide derivatives
US6919343B2 (en) 2002-02-08 2005-07-19 Merck & Co., Inc. N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
CA2479338A1 (en) 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
EP1496896A4 (en) 2002-04-08 2007-10-31 Merck & Co Inc AKT INHIBITORS EFFECT
AU2003230802B2 (en) 2002-04-08 2007-08-09 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DE10216368A1 (de) 2002-04-12 2003-10-16 Henkel Kgaa Arylsulfatase-Inhibitoren in Deodorantien und Antitranspirantien
MY134200A (en) 2002-04-12 2007-11-30 Kowa Co Method for treating cancer
US20030229149A1 (en) 2002-05-28 2003-12-11 Werner Baschong Anti-inflammatory agents
GB0216233D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
GB0216252D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
GB0216224D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
US20040044041A1 (en) 2002-08-06 2004-03-04 Kuduk Scott D. 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives
US20040034064A1 (en) 2002-08-06 2004-02-19 Kuduk Scott D. 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives
US20040063761A1 (en) 2002-08-06 2004-04-01 Kuduk Scott D. 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives
SE0202692D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
WO2004037816A1 (en) * 2002-10-28 2004-05-06 Chugai Seiyaku Kabushiki Kaisha Benzofuran compounds having antitumor activity
WO2004052488A2 (en) 2002-12-03 2004-06-24 Bristol-Myers Squibb Company Process for removing metals from liquids
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
PT1567490E (pt) 2002-12-04 2011-12-09 Univ Virginia Commonwealth Agentes contra a falciformação
AU2003289200A1 (en) 2002-12-06 2004-06-30 Kowa Co., Ltd. Erythropoietin production accelerator
DE10257357A1 (de) 2002-12-09 2004-06-24 Bayer Ag Fluorhaltige Benzaldehyde
WO2004056727A2 (en) 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
ATE495794T1 (de) * 2003-02-05 2011-02-15 Desi Raymond Richardson Metallionenchelatoren und ihre therapeutische verwendung
JP4331954B2 (ja) 2003-02-13 2009-09-16 株式会社リコー ユニット支持装置および画像形成装置
EP1597938A2 (en) 2003-02-28 2005-11-23 Ciba SC Holding AG Electroluminescent device
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
CN1791580A (zh) 2003-03-24 2006-06-21 麦克公司 联芳基取代的6元杂环钠通道阻滞剂
EP1620089A4 (en) 2003-03-26 2008-12-24 Crc For Asthma Ltd Therapeutic and prophylactic compositions and their uses
EP1615895A4 (en) 2003-04-03 2007-11-07 Merck & Co Inc BIARYLSUBSTITUTED PYRAZOLE AS SODIUM CHANNEL BLOCKER
WO2004094379A2 (en) 2003-04-16 2004-11-04 Amgen Inc. 3-phenyl-4- (pyrimidin-2-yl) -6- (piperidin-4-yl) derivatives and related compounds as tnf-alpha and il-1 inhibitors for the treatment of inflammations
US20070060584A1 (en) 2003-04-18 2007-03-15 Chakravarty Prasun K Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
US20040223912A1 (en) 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
DK1638544T3 (da) 2003-05-07 2008-03-31 Univ Aberdeen Ketoner og reducerede ketoner som terapeutiske midler til behandling af knogletilstande
WO2004100998A2 (en) 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
GB0312654D0 (en) 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
FR2857010B1 (fr) 2003-07-01 2005-09-16 Servier Lab Nouveaux derives bicycliques alkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2005009993A1 (en) 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
BRPI0412257A (pt) 2003-07-23 2006-10-03 Synta Pharmaceuticals Corp compostos para inflamação e usos imuno-relacionados
EP1653148B1 (en) 2003-07-25 2018-05-02 Toyota Jidosha Kabushiki Kaisha Gas supply system
WO2005016862A1 (en) 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
CN100591745C (zh) 2003-09-05 2010-02-24 西巴特殊化学品控股有限公司 电致发光装置
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
JP4634303B2 (ja) 2003-10-10 2011-02-16 興和株式会社 血管新生抑制薬
US6990935B2 (en) 2003-10-27 2006-01-31 Borgwarner Inc. Pivoting lifter control system using spool valve and check valve to recirculate oil
CN1890223A (zh) 2003-10-31 2007-01-03 神经能质公司 辣椒素受体促效剂
AR046698A1 (es) 2003-11-11 2005-12-21 Ishihara Sangyo Kaisha Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo
JP2007518703A (ja) 2003-11-26 2007-07-12 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド ２−（ｐ−トリフェニル）−３−フェニルピラジン誘導体を含むエレクトロルミネセンス装置
US7119208B2 (en) 2003-12-03 2006-10-10 Virginia Commonwealth University Anti-sickling agents
WO2005063222A1 (ja) 2003-12-26 2005-07-14 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
US20050165025A1 (en) 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
US7501510B2 (en) 2004-03-26 2009-03-10 The University Of Hong Kong Thiourea compositions and uses thereof
FR2868417B1 (fr) 2004-04-02 2006-06-23 Rhodia Chimie Sa Procede de formation d'une liaison carbone-carbone
JP2006151946A (ja) 2004-04-30 2006-06-15 Konishi Kagaku Ind Co Ltd ジアリール誘導体の製造方法
GB0412874D0 (en) 2004-06-09 2004-07-14 Pfizer Ltd Novel pharmaceuticals
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
DE102004035322A1 (de) 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
FR2874611B1 (fr) 2004-08-31 2006-11-17 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006029850A1 (en) * 2004-09-14 2006-03-23 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
TW200631949A (en) 2004-10-28 2006-09-16 Inst For Pharm Discovery Inc Substituted carboxylic acids
JP2006135153A (ja) 2004-11-08 2006-05-25 Canon Inc ビルドアッププリント配線基板および電子部品との接合構造
US20080132509A1 (en) 2004-12-13 2008-06-05 Neurogen Corporation Substituted Biaryl Analogues
WO2006074919A2 (de) 2005-01-12 2006-07-20 Curacyte Discovery Gmbh 3 -AMINO- 6-ARYL (BZW.6-HETEROARYL) -THIENO [2 , 3-B] PYRIDIN-2-CARBONSÄUREAMIDE, DIESE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN UND IHRE VERWENDUNG ALS INHIBITOREN DER TNFα-FREISETZUNG
US20090123563A1 (en) * 2005-02-07 2009-05-14 Novo Nordisk A/S Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
JP3839454B2 (ja) 2005-02-07 2006-11-01 三菱電機株式会社 内燃機関の制御装置
JP2008530048A (ja) 2005-02-11 2008-08-07 バイエル・クロツプサイエンス・エス・アー ピリジルメチルベンズアミド誘導体及びチアゾールカルボキサミド誘導体を含んでいる殺菌剤組成物
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US7691848B2 (en) 2005-03-02 2010-04-06 Wyeth Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
JP5159303B2 (ja) 2005-03-03 2013-03-06 武田薬品工業株式会社 放出制御組成物
DE102005009705A1 (de) 2005-03-03 2006-09-07 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
TW200702363A (en) 2005-04-05 2007-01-16 Sumitomo Chemical Co Crosslinked polymer electrolyte and method for producing the same
US7482027B2 (en) 2005-04-30 2009-01-27 Angiolab, Inc. Composition for the prevention or treatment of diseases associated with angiogenesis
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2006124581A2 (en) 2005-05-12 2006-11-23 Wyeth Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (fsh-r) antagonists
CA2607883A1 (en) 2005-05-12 2006-11-23 Wyeth Pyrrolobenzodiazepines and heteroaryl, aryl and cycloalkylamino ketone derivatives as follicle stimulating hormone receptor (fsh-r) antagonists
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
RU2007146444A (ru) 2005-05-13 2009-06-20 Лексикон Фармасьютикалз, Инк. (Us) Полициклические соединения и способы их применения
EP1888549A2 (en) 2005-05-19 2008-02-20 Vertex Pharmaceuticals, Inc. Biaryls useful as modulators of ion channels
AU2006258007A1 (en) 2005-06-09 2006-12-21 Wyeth Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
WO2007017143A1 (en) 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
WO2007020888A1 (ja) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited 脳・神経細胞保護剤および睡眠障害治療薬
EP1922383A1 (en) 2005-08-26 2008-05-21 Koninklijke Philips Electronics N.V. Substrate material for handling and analysing samples
WO2007027878A2 (en) 2005-08-31 2007-03-08 Emergent Product Development Gaithersburg Inc. 4-substituted 2-aryloxyphenol derivatives as antibacterial agents
AR056869A1 (es) 2005-09-13 2007-10-31 Bayer Cropscience Ag Composicion fungicida que comprende un derivado arilamidina y dos compuestos fungicidas conocidos
AU2006290715A1 (en) 2005-09-13 2007-03-22 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine H4 receptor activity
JP2007084415A (ja) 2005-09-17 2007-04-05 Chikosha:Kk 木材チップを混入した軽量注入材。
WO2007034277A1 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists
JP2007084454A (ja) 2005-09-20 2007-04-05 Fujifilm Corp スルホニウム化合物の製造方法
DE102005045132A1 (de) 2005-09-22 2007-03-29 Archimica Gmbh Verfahren zur Herstellung von 2-Arylcarbonylverbindungen, 2-Arylestern und 2-Arylnitrilen sowie ihrer heteroaromatischen Analoga
GB0519651D0 (en) 2005-09-27 2005-11-02 Univ Nottingham Ferrocenyl phosphite ligands for asymmetric catalysis and a method for their production
WO2007056155A1 (en) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
CN1958568B (zh) 2005-11-03 2011-04-13 中国科学院上海药物研究所 一类预防或治疗幽门螺杆菌感染化合物、其制法和用途
US8017331B2 (en) 2005-11-04 2011-09-13 Mannkind Corporation IRE-1α substrates
JP2009516691A (ja) 2005-11-21 2009-04-23 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド Ｑｔ間隔延長およびこれに伴う疾病の治療
CN101351458A (zh) 2005-12-01 2009-01-21 匹兹堡大学 作为促淀粉样变蛋白成像剂的同位素标记的苯并噻唑化合物
ATE473957T1 (de) 2005-12-02 2010-07-15 Finorga Sas Verfahren zur herstellung aromatischer derivate von 1-adamantan
JP2009517457A (ja) 2005-12-02 2009-04-30 フィノルガ ソシエテ パル アクションス シンプリフィ 中間体及び１−アダマンタンの芳香族誘導体の調製方法
US8486983B2 (en) 2005-12-05 2013-07-16 Merck Sharp & Dohme Corp. Self-emulsifying formulations of CETP inhibitors
TW200732313A (en) 2005-12-15 2007-09-01 Astrazeneca Ab Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
CN103214450B (zh) 2005-12-28 2016-10-05 弗特克斯药品有限公司 作为atp-结合盒转运蛋白调节剂的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物
KR20140107671A (ko) 2005-12-30 2014-09-04 머크 샤프 앤드 돔 코포레이션 Ｃｅｔｐ 억제제로서 유용한 1,3-옥사졸리딘-2-온 유도체
WO2007077457A2 (en) 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
GB0601031D0 (en) 2006-01-18 2006-03-01 Novartis Ag Organic compounds
WO2007092930A2 (en) 2006-02-08 2007-08-16 Regents Of The University Of California Method of treatment for mycobacterium tuberculosis
US20090291857A1 (en) * 2006-02-27 2009-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods to identify inhibitors of the unfolded protein response
AU2007201027B2 (en) 2006-03-08 2009-10-22 National Institute Of Immunology 2-thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-acp reductase of type II fatty acid synthesis pathway and other cell growth pathways
EP2010529A1 (en) 2006-04-10 2009-01-07 PainCeptor Pharma Corp. Compositions and methods for modulating gated ion channels
US20070249607A1 (en) 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
US20080064717A1 (en) 2006-05-19 2008-03-13 Rajesh Iyengar Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
WO2008002246A1 (en) 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
PL2054405T3 (pl) 2006-07-11 2014-03-31 Dae Woong Pharma Nowe pochodne biarylobenzimidazolu i zawierająca je kompozycja farmaceutyczna
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK2420494T3 (en) 2006-08-16 2015-01-12 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine 3-monooxygenase
US20080076800A1 (en) 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
WO2008030752A2 (en) 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
WO2008037266A1 (en) 2006-09-25 2008-04-03 Universite Libre De Bruxelles Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
WO2008042892A2 (en) 2006-10-02 2008-04-10 N.V. Organon Fatty acid amide hydrolase inhibitors for energy metabolism disorders
CN102015606B (zh) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1α抑制剂
JP5127330B2 (ja) 2007-07-12 2013-01-23 日立造船株式会社 光電変換素子およびその製造方法
JP5127335B2 (ja) 2007-07-17 2013-01-23 三井造船株式会社 接続部の構造、バラ積み貨物荷役装置及び接続部の気密保持方法
JP2009149797A (ja) 2007-12-21 2009-07-09 Tohoku Carbon Kk 木炭粉含有塗料組成物及びその塗装方法
USD675543S1 (en) 2011-07-26 2013-02-05 Gizmode, LLC Moisture detection device
JP6135153B2 (ja) 2013-01-30 2017-05-31 井関農機株式会社 管理機

Also Published As

Publication number Publication date
EP2155643B1 (en) 2016-08-10
CN103450077A (zh) 2013-12-18
US20110065162A1 (en) 2011-03-17
JP5684585B2 (ja) 2015-03-11
HK1176601A1 (en) 2013-08-02
WO2008154484A1 (en) 2008-12-18
ES2569660T3 (es) 2016-05-12
US9241942B2 (en) 2016-01-26
US20160168116A1 (en) 2016-06-16
EP2155643A1 (en) 2010-02-24
JP5941173B2 (ja) 2016-06-29
EP2520561B1 (en) 2016-02-10
US9546149B2 (en) 2017-01-17
JP4827986B2 (ja) 2011-11-30
JP2015091863A (ja) 2015-05-14
EP3150589A1 (en) 2017-04-05
JP2010529147A (ja) 2010-08-26
EP2520561A1 (en) 2012-11-07
CA2963784A1 (en) 2008-12-18
CN102015606B (zh) 2015-02-04
US8614253B2 (en) 2013-12-24
US20140080832A1 (en) 2014-03-20
MX2009013332A (es) 2010-01-25
CN102015606A (zh) 2011-04-13
JP2014055129A (ja) 2014-03-27
ES2601856T3 (es) 2017-02-16
JP2011121964A (ja) 2011-06-23
US20170152206A1 (en) 2017-06-01
US20090186893A1 (en) 2009-07-23
US9981901B2 (en) 2018-05-29
US7858666B2 (en) 2010-12-28
EP2532643A1 (en) 2012-12-12
CN103450077B (zh) 2016-07-06
CA2690913A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
CA2690913C (en) Ire-1.alpha. inhibitors
US9856266B2 (en) IRE-1alpha inhibitors
HK1179602A (en) Ire-1a inhibitors
HK1139383B (en) Ire-1a inhibitors
HK1176601B (en) Ire-1a inhibitors
HK1192249A (en) Ire-1a inhibitors
HK1192249B (en) Ire-1a inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130607

MKLA Lapsed

Effective date: 20210609